May 24, 2024, BioCellgraft, Inc. New York, NY. Announces several advancements supporting the forthcoming commercial launch of the first injectable regenerative acellular placental derived tissue enhancement solution for acute procedures in dentistry as well as both preventive care in soft tissue concerns and aesthetic opportunities for patients. These advances the company is reporting are a direct result of the exceptional participation of BCG’s strategically selected Key Opinion Leaders (KOLs) and active practitioners working with OraFyl™ the company’s Human Connective Tissue Matrix (HCTM) developed and manufactured by Celularity, Inc. and exclusively licensed to BioCellgraft for all applications pertaining to oro-maxillofacial procedures. Additional support from the newly formed Celularity/BioCellgraft Oral Healthcare Collaborative Working Group consisting of key members of each company’s science and research team inclusive of practitioners, educators and trainer helps drive continued data collection supporting the tremendous success and broad application for oral care these products offer practitioners and patients alike.
The success of the collaboration prompted Celularity to invite BioCellgraft to establish a cell culture lab, procedure operatories and training and education on site at Celularity HQ in Florham Park, NJ. The lab, offices and facilities for BioCellgraft at Celularity will begin the week of May 19, 2024 with the expectation of beginning product orders in the coming weeks. The company’s lab which has been designed by Michel Dard, DDS, MS, PhD, CEO of BioCellgraft Inc., will be chaired and directed by carefully selected practicing implantologists, periodontists that also are active professors educating in oral health related soft and hard tissue conditions. These individuals are extremely well respected and known in the world of oral healthcare.“Together with the extremely talented Celularity team, we are setting up the utmost advanced holistic and comprehensive structure in oro-dental, maxillofacial pre-clinical, translational and clinical research under a clinical development model for the benefits of our partners, stakeholders, practitioners and their patients.” Says, BioCellgraft CEO, Dr. Michel Dard.
The company is looking forward to announcing the team once it is fully assembled. The company also looks forward to beginning the work that is planned at the Celularity / BioCellgraft Labs and procedure center. “We are tremendously excited to work so closely with our partner at Celularity on their campus. Their massive expertise and passion for regenerative therapeutics inspires the energy and awesome culture we experience each time we drive on to campus and walk through the doors. This is all about delivering solutions to the patients who need them through practitioners that are so delighted to have these game changing options as a tool.” Says Michael Wilhelm, Chairman, Founder and EVP of Partnerships for BioCellgraft. BioCellgraft’s laboratory and procedure center at Celularity will support cell culture research that will help develop innovative uses for the already FDA designated products as well as drive new discoveries.
Additionally, treatments will be performed by licensed dental experts in the areas of periodontal care and aesthetics such as thin biotype (gingival thickness), black triangles (papilla loss) and gingival recession as well as an elected procedure option for plumping lips and cheek contouring. Studies have shown that Black Triangles can occur in up to 67% of people over 20 years of age, making this a rather common condition that needs treating otherwise, more costly and detrimental health issues can arise. The global periodontal market (soft and hard tissue procedures) enjoyed a US$10 billion year in 2022 and will further expand at a CAGR of 10.4% to reach a valuation of US$24.4 billion in year 2032. The supplementation of additional regenerative properties to our existing portfolio of products at BioCellgraft gives the physician and the patient even better outcomes in their treatment regimens.The global dermal fillers market size was valued at $5 billion in 2023, projected to grow to $5.44 billion in 2024 and $10.16 billion by 2032. Dermal fillers in the US alone were just at $2 billion in 2023
About BioCellgraft, Inc.
In the realm of oral health, the absence of effective regenerative therapies for soft and hard tissues remains a significant concern. Patients worldwide grapple with issues such as degenerating gums, gum recession, and thin biotypes, necessitating innovative solutions.
BioCellgraft is a pioneering oral healthcare focused development and commercialization company driven by experienced dental experts and educators aimed at revolutionizing oral healthcare through groundbreaking regenerative therapies. BioCellgraft represents the epitome of innovation in oral healthcare, catering to unmet needs within the dental landscape. Our focus lies in the development and delivery of regenerative treatments that enhance both soft and hard tissue in the oral cavity. Leveraging the Human Connective Tissue Matrix (HCTM), our suite of products introduces novel possibilities in tissue regeneration.
To learn more, visit: www.biocellgraft.com
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing, and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. BioCellgraft, Inc expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
1-646-502-5501 EXT 102